Galectin Therapeutics Inc. (GALT)

[Amatuer17]

As per today's PR - yes

Now the question efficacy - the FX trial failed.
What is difference between efficacy indications for FX and CX?
Why CX is supposed to succeed when FX failed - same drug, same target organ and advanced form of disease?

So yes - the efficacy is what matters.

With the possible downside - one should consider Jan 2018 options